Summary The endocrine effects of 125mg (low dose) aminoglutethimide (AG) twice daily (b.d.) were compared with those of 125mgAG+20mg hydrocortisone (HC) b.d. in 23 and 45 postmenopausal patients with advanced breast cancer, respectively. The patients in each group were drawn from two separate populations, but the mean age and weight of the groups were similar and there were no significant differences between the pretreatment serum levels of the hormones investigated. Serum oestrone and oestradiol levels were suppressed by both treatments, but there was a significantly greater suppression by AG+HC. This greater suppression is probably due to the observed increase in serum androstenedione (i.e. precursor) levels with AG alone, whilst with AG +HC these levels were found to be reduced. In terms of suppression of serum oestrogen levels it is of benefit to combine low dose AG with HC.
The clinical effectiveness of aminoglutethimide (AG) in postmenopausal breast cancer patients was initially thought to be due to its inhibition of the adrenal 20,22 desmolase enzyme, which catalyses the conversion of cholesterol to pregnenolone (Cash et al., 1967) . AG was therefore used with the aim of achieving a 'medical adrenalectomy' (Lipton & Santen, 1974; Smith et al., 1978; Wells et al., 1978) in a dose of 750-1,000mgd-1 in combination with hydrocortisone (HC, . Oestrogen levels are suppressed by AG+HC but it is now accepted that the major, if not sole, mechanism by which AG suppresses oestrogen levels is its potent inhibition of peripheral aromatase, the enzyme complex which converts circulating androgens to oestrogens (Harris et al., 1983a; Nagel & Santen, 1984; Stuart-Harris et al., 1984 . This has led to a reassessment of the use of AG in breast cancer patients. In particular, the recognition of the greater potency of AG in vitro on the aromatase than on the desmolase enzyme (Graves & Salhanick, 1979) (Harris et al., 1983a; Stuart-Harris et al., 1984 and this finding led to clinical trials examining the effectiveness of this dose both with and without HC (Cantwell et al., 1984; StuartHarris et al., 1984) . Blood samples from patients from these two studies have been assayed to determine the relative effectiveness of the treatments in the suppression of postmenopausal oestrogen levels. Stuart-Harris et al., 1985 [oestrone]). All samples from each patient were assayed in the same batch but the inclusion of patients from each group in a particular batch was randomised.
Results
There was no significant difference between the two treatment groups in either the mean age or weight of the patients. As treatment progressed patients who did not respond or who relapsed were withdrawn and there were therefore less samples available for analysis. For this reason the comparison of endocrine effects was made between samples taken before and after 1, 2, 3-4, 5-6 and >6 months treatment. If more than one sample was available during any of the intervals the mean value was calculated and used for comparison.
The mean levels of oestrone, oestradiol, androstenedione and DHAS before and during treatment are shown for both groups in Figure 1 there was no significant difference between the treatments in their effects on the levels of oestradiol. Since pretreatment oestradiol levels were different between the two groups, the suppression of oestradiol as a percentage of pretreatment level was compared between the groups (Figure 2) . Throughout the study the mean value in the AG + HC group varied within the range of 35-45% of of baseline, whilst in the AG alone group the values remained between 50 and 60% (except at 3-4 months where a single value of 240% markedly raised the mean and exclusion of that value gave a mean of 59.2%). The levels at 1 month were significantly different between treatment groups (t-test, P<0.01) and an analysis of variance showed a significant Table I with the suppression found in our two previous endocrine studies, where there was no significant difference in suppression of either oestrogen between 250mg AG and 1,000mg AG + 40mg HG daily.
Discussion
The observation that the side effects of AG are (Grodin et al., 1973; James et al., 1981; Cleland et al., 1985) . In the present study these factors were similar in the two groups. The lack of significant difference between the groups in the pretreatment levels of the analytes also supports the comparability of the groups.
Oestrone levels were clearly suppressed to a greater extent by AG + HC than AG alone. It is probable that this relates to the respective changes in the levels of androstenedione, a substrate for peripheral aromatisation and the immediate precursor of oestrone, which occurred in the two treatment groups. The levels are increased on the group treated with AG alone, probably because of its inhibition of the 11-and 21-hydroxylases (Harris et al., 1983a) . Combination of HC with 1,000mg AG daily has previously been shown to have little effect on androstenedione levels (Samojlik et al., 1980; Harris et al., 1983a Harris et al., , 1984 , but in this study combination with low dose AG led to a marked suppression. AG at a dosage of 125mg b.d. reduces peripheral aromatoase activity by 92% . It seems likely that the small residual activity combined with an increase in precursor levels as occurs with AG alone, resulted in the less marked suppression of oestrone in that group. It is probable that the effect on oestradiol levels was greater with AG + HC, although statistically this could be shown only after conversion of the values to percentages of pretreatment level. Consideration of the current results and those of our previous reports, which indicated no significant difference in oestrogen suppression between 250mg AG alone and 1,000mg AG + 40mg HC daily (Harris et al., 1983a; Stuart-Harris et al., 1985) , might lead to the suggestion that 250mg AG + HC may be more effective than 1,000mg AG + HC in this respect. However, it is probable that this is not the case since in the earlier studies there was a trend towards greater oestrogen suppression by the higher dose with HC (as shown in Table I ) although this was not statistically significant. In addition, the suppression found in the present study was no greater than that found for either oestrogen in patients on treatment with 1,000mgAG+HC in our first study of low dose AG (Harris et al., 1983a) .
In much of the work on the endocrine effects of AG+ HC, DHAS has been used as a marker of adrenal androgen activity. The results of this study show a marked non-parallelism in the changes in DHAS and androstenedione levels, particularly in the group treated with AG alone. This is probably a reflection of the effects of AG on cytochrome P450 mediated steroidogenic enzymes other than the 20,22 desmolase and it indicates that DHAS is not necessarily a useful marker of adrenal androgen secretion.
In conclusion, the difference in the levels of both oestrogens between the two treatment groups indicates that the combination of HC with low dose AG is beneficial in attempting to achieve maximal oestrogen suppression, and may be significant in determining the efficacy of low dose AG in the suppression of oestrogen-dependent breast cancer growth.
